Side-by-side · Research reference
KPVvsLivagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongAUTO-DRAFTED13/39 cited
BAnimal-StrongHUMAN-REVIEWED20/32 cited
KPV
α-MSH C-terminal · Anti-inflammatory
SQ / oral / topical · Local · Daily or 2-3×/week
Livagen
Khavinson Bioregulator · Hepatoprotective Tetrapeptide
Oral or SQ · Tissue-specific to liver
01Mechanism of Action
Parameter
KPV
Livagen
Primary target
Intracellular targets bypassing melanocortin receptors (proposed)Dalle-Pang 2024
Hepatocyte protein synthesis machineryBrodskiĭ 2001
Pathway
NF-κB inhibition + cytokine modulation (TNF-α, IL-1β, IL-6) → reduced inflammationDalle-Pang 2024
Tissue-specific bioregulator → Hepatocyte stimulation → Protein synthesis normalizationBrodskiĭ 2001Khavinson 2001
Downstream effect
Anti-inflammatory action without α-MSH pigmentation effects; gut barrier protectionDalle-Pang 2024
Age-dependent enzyme normalization, hepatoprotection in fibrosis/hepatitis models, elevated protein synthesis in senescent hepatocytes
Feedback intact?
No melanocortin receptor binding
—
Origin
Synthetic tripeptide; the C-terminal Lys-Pro-Val residues of α-MSH (residues 11-13)Dalle-Pang 2024
Directed chemical synthesis from amino acid analysis of liver polypeptide preparations (Ventvil)
Antibody development
—
—
02Dosage Protocols
Parameter
KPV
Livagen
Frequency
Daily or 2–3× per week
—
Lower / starter dose
100 mcg / day
—
Evidence basis
Animal-strong + emerging clinical data in IBDDalle-Pang 2024
Animal models (rats, 1–24 months age); in vitro hepatocyte cultureTimofeeva 2005Brodskiĭ 2001Khavinson 2002
Duration
4–8 weeks per cycle
—
Reconstitution
Bacteriostatic water (SQ form)
—
Timing
No specific time; often taken with / before meals (oral)
—
Half-life
Hours (estimated; rapid tissue uptake)
—
Animal dose (oral)
—
Not specified in abstracts; 2-week administration protocolTimofeeva 2005
Per os administration in rats.
Duration (experimental)
—
2 weeks (enzyme study); up to 24 months (cell culture)Timofeeva 2005Brodskiĭ 2001
Route
—
Oral or subcutaneous
Resists peptidase hydrolysis, enabling oral bioavailability.Timofeeva 2005
Human data
—
None in provided literature
04Side Effects & Safety
Parameter
KPV
Livagen
Injection site reaction
Mild irritation
—
GI symptoms
Rare nausea (oral form)
—
Long-term safety
Limited human data
—
Pregnancy / OB
Avoid — insufficient data
—
Reported adverse effects
—
None documented in animal studies
Human safety data
—
No human trials in provided literature
Absolute Contraindications
KPV
- ·Pregnancy / breastfeeding
Livagen
—Relative Contraindications
KPV
- ·Active autoimmune disease (theoretical)
Livagen
—05Administration Protocol
Parameter
KPV
Livagen
1. Reconstitution
Add 1 mL bacteriostatic water to vial per labelling.
Oral administration supported by peptidase resistance. Subcutaneous route used in organotypic culture experiments.Timofeeva 2005Khavinson 2001
2. Form
SQ injection (acute), oral capsule (chronic / gut), topical for skin indications.
No specific timing documented. Two-week protocols used in animal models with daily administration.Timofeeva 2005
3. Timing
Morning preferred; oral form taken with / before meals.
Elderly individuals may exhibit different enzyme normalization patterns than younger cohorts, based on rat age-stratified findings.Timofeeva 2005
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
—
5. Needle
29–31G insulin syringe (SQ form).
—
06Stack Synergy
KPV
+ BPC-157
StrongKPV (NF-κB inhibition, cytokine reduction) + BPC-157 (VEGF-driven angiogenesis, tissue regeneration) form the classic gut-healing stack. KPV reduces inflammatory drive; BPC-157 promotes mucosal repair. Anecdotally favoured for IBD, ulcerative colitis, and post-surgical gut recovery.
- KPV
- 200–500 mcg oral · daily
- BPC-157
- 250–500 mcg oral or SQ · daily
- Primary benefit
- Combined anti-inflammation + mucosal repair for gut conditions
Livagen
— no documented stacks